Sharemaestro company-news research for BioNTech SE (BNTX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest BNTX news and sentiment
BioNTech SE
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
42 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone47/100
→
Published 30-day score50/100
Latest source headline
Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?
finance.yahoo.com · 07 Oct 2026 21:12
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
42 current stories are mapped specifically to BNTX.
The score uses 7 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.173.
Confidence is 20/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
94%/100
Company news42 company stories
84/100
Story agreement16/100 difference
News history
Daily score and story count over 30 days
10 Sep25 Sep09 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.173 after freshness weightingSource breadth100
7 independent publishersCompany relevance94
share tied directly to this companyFreshness22
recency-weighted evidenceAgreement84
how closely stories agreePublisher mix72
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202647USD 96.9-1.6%
25 Sep 202652USD 98.52+2.6%
18 Sep 202651USD 96.06-0.7%
11 Sep 202649USD 96.73-6.8%
04 Sep 202649USD 103.76+1.7%
28 Aug 202649USD 102.075-12.4%
21 Aug 202652USD 116.57+25.2%
14 Aug 202644USD 93.09-0.6%
Provisional evidence
News subjects
What is shaping the score
Market update4520 stories · 48%
Earnings5210 stories · 24%
Regulatory and legal515 stories · 12%
Analyst action314 stories · 10%
Guidance523 stories · 7%
Source mix
Where the evidence comes from
Stock Titan415 stories · 12%
AD HOC NEWS445 stories · 12%
Simply Wall St.523 stories · 7%
24/7 Wall St.503 stories · 7%
The Globe and Mail712 stories · 5%
The Motley Fool562 stories · 5%
Insider Monkey512 stories · 5%
Recurring subjects
Subjects appearing most often
Life Sciences27Financial Markets19Earnings18Biotech11Clinical Trials8Oncology7Pharma5Lung Cancer3Finance3Valuation2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
27 Jul50 neutral09 Oct 14:19
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 09 Oct 14:19 | 49 | +0 | 23/100 (-1) | 42 (-4) | Provisional |
| 07 Oct 23:59 | 49 | +1 | 24/100 (-3) | 46 (0) | Provisional |
| 05 Oct 23:59 | 48 | +0 | 27/100 (-4) | 46 (0) | Provisional |
| 03 Oct 23:59 | 48 | +1 | 31/100 (-2) | 46 (+1) | Provisional |
| 02 Oct 23:59 | 47 | +0 | 33/100 (+1) | 45 (0) | Provisional |
| 01 Oct 23:59 | 47 | +0 | 32/100 (-3) | 45 (-1) | Provisional |
| 30 Sep 23:59 | 47 | -4 | 35/100 (+2) | 46 (+2) | Provisional |
| 28 Sep 23:59 | 51 | +0 | 33/100 (+5) | 44 (+5) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 42 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action3 stories
27.1%4.1%
Earnings2 stories
0.0%29.9%
Guidance1 story
0.0%20.1%
Market update5 stories
11.9%0.0%
Regulatory and legal1 story
0.0%6.9%
Each side uses the same scale: 0–29.9% of the retained directional evidence.
Where the influence comes from
47.3%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?
BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring of its manufacturing footprint and the oncology pipeline, the live question is how well the present US$95.73 price lines up with the revenue the company is generating and expects to generate. The stock has fallen 60.3% over 5 years, which raises the issue of whether the market is now pricing BioNTech more on
- Published
- 07 Oct 2026 21:12
- News subject
- Market update
- Why this score
- Negative valuation view, Negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechEarningsOncologyRestructuringShare PriceValuation
—Unscored
EarningsNot used in direction
BioNTech stock draws Moderate Buy consensus at USD 126 target
BioNTech stock received a "Moderate Buy" consensus from 19 brokerages with an average target price of USD 126, despite a challenging second quarter that saw significant GAAP net losses. While analysts anticipate a higher valuation, the company's financial performance highlights its depend…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech stock received a "Moderate Buy" consensus from 19 brokerages with an average target price of USD 126, despite a challenging second quarter that saw significant GAAP net losses. While analysts anticipate a higher valuation, the company's financial performance highlights its dependence on its oncology pipeline as COVID-19 vaccine revenue decreases. The stock's current trading price of USD 97.10 is 29.7% below the analyst target and USD 26.90 below its 52-week high of USD 124.00.
- Published
- 05 Oct 2026 18:26
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading
BioNTech announced it would close three German sites after failing to sell them, marking a shift away from pandemic-era manufacturing. The company's stock was trading at EUR 86.10 in weekend trading, matching its previous closing price. This news follows a recent release of updated trial …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech announced it would close three German sites after failing to sell them, marking a shift away from pandemic-era manufacturing. The company's stock was trading at EUR 86.10 in weekend trading, matching its previous closing price. This news follows a recent release of updated trial data for their cancer treatment, gotistobart, showing promising results.
- Published
- 03 Oct 2026 13:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife SciencesManufacturing
40/100 tone
BioNTech CEO Ugur Sahin sold 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and another 17,000 shares on October 2, 2026, at $96.7249 per share. These sales were executed under a pre-established Rule 10b5-1 trading plan. Sahin also holds a significant indirect stake of …
7.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin sold 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and another 17,000 shares on October 2, 2026, at $96.7249 per share. These sales were executed under a pre-established Rule 10b5-1 trading plan. Sahin also holds a significant indirect stake of 39,218,111 shares through Medine GmbH, where he is the sole shareholder, with a portion of these held in a trust arrangement.
- Published
- 02 Oct 2026 20:34
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 7.9% of directional evidence · 6.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
EarningsNot used in direction
BioNTech SE (BNTX) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-Co…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.
- Published
- 01 Oct 2026 16:05
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
42/100 tone
BioNTech CEO Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 and 32,000 ordinary shares at $98.1203 on September 29 and September 30, 2026, respectively. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Sahin also indire…
3.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 and 32,000 ordinary shares at $98.1203 on September 29 and September 30, 2026, respectively. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Sahin also indirectly beneficially owns 39,218,111 ordinary shares through Medine GmbH, which holds voting power over 106,721 shares in a trust for an individual.
- Published
- 30 Sep 2026 20:27
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 3.2% of directional evidence · 8.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
EarningsNot used in direction
BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial
BioNTech announced the Dareon-Rosetta35 trial, a Phase Ib/II study evaluating new cancer drugs, obrixtamig and pumitamig, for advanced small cell lung cancer. This trial, a partnership with Boehringer Ingelheim, aims to assess drug tolerability and tumor response, marking BioNTech's expan…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech announced the Dareon-Rosetta35 trial, a Phase Ib/II study evaluating new cancer drugs, obrixtamig and pumitamig, for advanced small cell lung cancer. This trial, a partnership with Boehringer Ingelheim, aims to assess drug tolerability and tumor response, marking BioNTech's expansion into solid tumors beyond vaccines. The study is interventional and open-label, focusing on safety and early signs of efficacy, and could provide a new revenue stream for BNTX if successful.
- Published
- 30 Sep 2026 16:27
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. Moderna appears to be further along in this diversification, with approved respiratory vaccines and positive late-stage oncology results. Bi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. Moderna appears to be further along in this diversification, with approved respiratory vaccines and positive late-stage oncology results. BioNTech, while having a broader oncology pipeline, faces greater challenges with revenue replacement as COVID-19 vaccine demand normalizes and has experienced recent clinical setbacks.
- Published
- 30 Sep 2026 15:27
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechCovid 19EarningsFinancial MarketsLife SciencesOncology
21/100 tone
Analyst action
BioNTech stock trades at EUR 86.05 after a revenue miss
BioNTech's stock is trading at EUR 86.05 following a significant revenue miss in Q2 2026, with revenue dropping by 59.50% to EUR 105.6 million. The company also reported a GAAP net loss and reduced its full-year revenue guidance, as its transition from COVID vaccine revenue to oncology gr…
22.6% of directional evidence
High story strength
Scoring detailsDirect company coverage
BioNTech's stock is trading at EUR 86.05 following a significant revenue miss in Q2 2026, with revenue dropping by 59.50% to EUR 105.6 million. The company also reported a GAAP net loss and reduced its full-year revenue guidance, as its transition from COVID vaccine revenue to oncology growth faces challenges, including the termination of a Phase 2 colorectal cancer trial. Despite these setbacks, Berenberg raised its price target for BioNTech to USD 140.00 with a Buy rating.
- Published
- 30 Sep 2026 14:32
- News subject
- Analyst action
- Why this score
- Missed expectations, Guidance cut
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 60/100
- 30-day weight
- 22.6% of directional evidence · 9.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
GuidanceNot used in direction
BioNTech (NasdaqGS:BNTX) Stock Forecast & Analyst Predictions
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 07:00
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
A trading plan covers BioNTech (BNTX) CEO Ugur Sahin's sales of 27,000 and 34,000 shares.
BioNTech CEO Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, and 34,000 ordinary shares on September 28, 2026, both executed under a Rule 10b5-1 trading plan established in June 2026. The sales were priced at $98.6882 and $98.4682 per share, respectively.…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, and 34,000 ordinary shares on September 28, 2026, both executed under a Rule 10b5-1 trading plan established in June 2026. The sales were priced at $98.6882 and $98.4682 per share, respectively. Sahin retains significant indirect holdings through Medine GmbH.
- Published
- 28 Sep 2026 21:23
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits
[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https:…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]), and Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) to dismiss lawsuits filed against them by Bayer's (BAYZF [https://seekingalpha.com/symbol/BAYZF])(BAYRY [https://seekingalpha.com/symbol/BAYRY]) Monsanto unit regarding the drugmakers' use of a patent related to mRNA te
- Published
- 28 Sep 2026 20:38
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechM APatent DisputeVaccines
—Unscored
Market updateNot used in direction
BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts
BioNTech announced it will close three German sites after failing to sell them. The company, known for its COVID-19 vaccine, has been restructuring and adjusting its operations. This move reflects ongoing efforts to optimize its asset portfolio.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech announced it will close three German sites after failing to sell them. The company, known for its COVID-19 vaccine, has been restructuring and adjusting its operations. This move reflects ongoing efforts to optimize its asset portfolio.
- Published
- 28 Sep 2026 16:23
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife SciencesMergers And Acquisitions
—Unscored
Market updateNot used in direction
BioNTech to close 3 German plants
BioNTech announced its decision to close three manufacturing plants in Germany. This move is part of the company's strategic adjustments. Further details regarding the reasons for closure and the impact are expected.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech announced its decision to close three manufacturing plants in Germany. This move is part of the company's strategic adjustments. Further details regarding the reasons for closure and the impact are expected.
- Published
- 28 Sep 2026 12:23
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life SciencesManufacturing
43/100 tone
4.6% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 11:06
- News subject
- Analyst action
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 4.6% of directional evidence · 11.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
57/100 tone
This article compares Moderna (MRNA) and BioNTech (BNTX) as investments in the mRNA cancer stock sector. It evaluates Moderna's clinical lead in cancer results against BioNTech's financial flexibility and broader oncology pipeline. The piece aims to determine which company offers a more a…
19.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
This article compares Moderna (MRNA) and BioNTech (BNTX) as investments in the mRNA cancer stock sector. It evaluates Moderna's clinical lead in cancer results against BioNTech's financial flexibility and broader oncology pipeline. The piece aims to determine which company offers a more attractive long-term setup for investors.
- Published
- 28 Sep 2026 10:42
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 19.5% of directional evidence · 11.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
BioNTech's investment narrative is shifting due to new lung cancer data and an updated COVID-19 vaccine. The investigational CTLA‑4 antibody gotistobart nearly doubled median overall survival in a Phase 3 lung cancer trial, boosting BioNTech's oncology pipeline. While COVID-19 vaccine rev…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech's investment narrative is shifting due to new lung cancer data and an updated COVID-19 vaccine. The investigational CTLA‑4 antibody gotistobart nearly doubled median overall survival in a Phase 3 lung cancer trial, boosting BioNTech's oncology pipeline. While COVID-19 vaccine revenue provides short-term cash flow, the company is heavily investing in oncology to secure long-term profitability, despite risks of prolonged losses and delayed approvals.
- Published
- 27 Sep 2026 01:10
- News subject
- Regulatory and legal
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechEarningsFinancial MarketsHealthcareLife SciencesOncology
—Unscored
EarningsNot used in direction
BioNTech SE (22UA.F) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-Co…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.
- Published
- 25 Sep 2026 10:53
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Form 4 BioNTech SE For: 25 September By Investing.com
This article announces the filing of a Form 4 for BioNTech SE on September 25. It is a brief financial news update indicating a regulatory filing concerning the company. The article also lists BioNTech's stock performance for the day.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article announces the filing of a Form 4 for BioNTech SE on September 25. It is a brief financial news update indicating a regulatory filing concerning the company. The article also lists BioNTech's stock performance for the day.
- Published
- 25 Sep 2026 08:53
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. The sales totaled approximately $6.84 million, with shares sold at prices of $99.4027 and $98.9913, respectively. Sahin still indirectly …
0.5% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. The sales totaled approximately $6.84 million, with shares sold at prices of $99.4027 and $98.9913, respectively. Sahin still indirectly holds over 39 million shares through Medine GmbH, where he is the sole shareholder.
- Published
- 24 Sep 2026 20:53
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 0.5% of directional evidence · 14.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
EarningsNot used in direction
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults a…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. Based on clinical, real-world, and manufacturing data demonstrating strong immune responses against circulating strains, the approval aligns with FDA strain guidance for fall 2026. You May Also Want to Look At: Pfizer (
- Published
- 24 Sep 2026 20:27
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetCovid 19 VaccineFda ApprovalPharma
—Unscored
Market updateNot used in direction
BNTX Stock Price and Chart — NASDAQ:BNTX
This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics. Recent developments include potential job cuts and site closures, ongoing patent litigation with Bayer CropScience, and a revised price target from …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics. Recent developments include potential job cuts and site closures, ongoing patent litigation with Bayer CropScience, and a revised price target from Citi. The company continues to be active in mRNA technology beyond COVID-19, with a focus on oncology and other therapies.
- Published
- 24 Sep 2026 13:00
- News subject
- Market update
- Why this score
- Operational disruption
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
71/100 tone
Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. This rating aligns with Morgan Stanley's Buy rating, though BMO Capital has a Hold rating on the stock. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP…
4.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. This rating aligns with Morgan Stanley's Buy rating, though BMO Capital has a Hold rating on the stock. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP net loss of $820.8 million for the quarter ending June 30.
- Published
- 24 Sep 2026 12:53
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 46/100
- 30-day weight
- 4.1% of directional evidence · 15.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
57/100 tone
BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. This increase followed a prior Nasdaq close of USD 97.71 on September 21, and the company had gained 5 percent year-to-date. The outlook also noted that BMO…
20.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. This increase followed a prior Nasdaq close of USD 97.71 on September 21, and the company had gained 5 percent year-to-date. The outlook also noted that BMO had recently lowered its 12-month target for BioNTech shares from USD 128 to USD 105.
- Published
- 22 Sep 2026 22:30
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 20.1% of directional evidence · 16.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan. Despite these sales, Sahin retains a significant indirect stake of 39,218,111 Ordinary Shares held via Medine GmbH, for which he is the sole shareholder. The transacti…
0.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan. Despite these sales, Sahin retains a significant indirect stake of 39,218,111 Ordinary Shares held via Medine GmbH, for which he is the sole shareholder. The transactions were executed at prices of $100.7182 and $97.8097 per share.
- Published
- 22 Sep 2026 20:54
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 0.2% of directional evidence · 16.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsLife Sciences
—Unscored
GuidanceNot used in direction
BioNTech price tries to regain footing - Forecast today - 23-09-2026
BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The ou…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The outlook remains bullish as long as support at $95.30 holds, with an expected target of $105.50 for its first resistance level.
- Published
- 22 Sep 2026 12:32
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that Bi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.
- Published
- 22 Sep 2026 09:54
- News subject
- Analyst action
- Why this score
- Analyst downgrade
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechCancerClinical TrialsEarningsFinancial MarketsLife Sciences
61/100 tone
BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious dis…
10.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious diseases. While financial metrics suggest caution, analyst ratings remain optimistic, highlighting a balance between innovative potential and financial health for investors.
- Published
- 22 Sep 2026 05:54
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 40/100
- 30-day weight
- 10.4% of directional evidence · 17.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncol…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncology validation. No new efficacy data was released Monday; the Presidential Symposium slot itself is the signal, as organizers reserve it for practice-changing datasets. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut. Ente
- Published
- 21 Sep 2026 15:45
- News subject
- Market update
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsModernaOncologyPrice TargetSplit
—Unscored
Market updateNot used in direction
BioNTech SE - American Depositary Shares (NQ: BNTX)
This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices,…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices, news, and research reports. The content primarily focuses on providing a framework for accessing financial data related to BioNTech SE.
- Published
- 19 Sep 2026 05:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
Earlier company news
BNTX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 124 older BNTX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to BNTX, but the headline and available text are not mainly about BioNTech SE. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of BNTX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.